Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery (FARES-2)

• ClinicalTrials.gov Identifier: NCT05523297
• Recruitment Status: Recruiting
• First Posted: August 31, 2022
• Last Update Posted: June 18, 2023
• Sponsor: Octapharma
• Information provided by (Responsible Party): Octapharma

Study Description

Brief Summary:

This is a multicentre, active-control randomized, prospective, Phase 3 study in adult cardiac surgery patients. Approximately 500 patients will be randomized at approximately 12 hospitals.

Condition or disease	Intervention/treatment	Phase
Bleeding Cardiac Surgery Patients	Drug: Octaplex; Drug: Frozen Plasma Product, Human	Phase 3

Detailed Description:

Patients will be randomized to receive either 4-factor PCC (Octaplex) or frozen plasma (FP).

The study will compare the hemostatic treatment response to Octaplex versus FP, defined as effective if no additional systemic or surgical hemostatic intervention is required from 60 minutes to 24 hours after initiation of the first treatment dose.

The study will include adult (≥18 years old) patients who undergo cardiac surgery with cardiopulmonary bypass (CPB) and require coagulation factor replacement due to bleeding post-CPB and after adequate reversal of heparin with protamine (as assessed by the surgical staff based on clinical and laboratory criteria) during surgery, and who have a known (e.g., as indicated by INR) or suspected coagulation factor deficiency.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 500 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Outcomes Assessor)
• Masking Description: Given the physical differences in the products and the emergency nature of the intervention, attending clinicians present during the infusion of the blood products/components will not be blinded to the treatment. To minimize bias, treating clinicians will be blinded to group assignments until immediately prior to IMP infusion.
• Primary Purpose: Treatment
• Official Title: Prospective, Multicentre, Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Bleeding Adult Cardiac Surgical Patients
• Actual Study Start Date: November 10, 2022
• Estimated Primary Completion Date: October 2024
• Estimated Study Completion Date: October 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Octaplex; Each participant to receive up to 2 Octaplex infusion intravenously within first 24 hours. Exceeding 24 hours frozen plasma will be administered	Drug: Octaplex; Prothrombin complex concentrate
Active Comparator: Frozen plasma; Each participant will be administered FP according to the local standard	Drug: Frozen Plasma Product, Human; If additional treatment is required after the maximum dose of IMP is administered or the treatment period has elapsed, patients in both groups will receive frozen plasma

Outcome Measures

Primary Outcome Measures :

1. Number of patients requiring additional hemostatic intervention [ Time Frame: 60 minutes to 24 hours after first dose of IMP ]
   Defined as 'effective' if no additional hemostatic intervention, such as administration of any systemic hemostatic agents (including platelets, cryoprecipitate, fibrinogen concentrate, activated recombinant factor VII, other coagulation factor products or a second dose of IMP) or any hemostatic interventions (including surgical re-opening for bleeding) is required from 60 minutes to 24 hours after initiation of the first dose of IMP.

Secondary Outcome Measures :

1. Number of patients requiring additional hemostatic intervention based on hemoglobin level [ Time Frame: 60 minutes to 24 hours after first dose of IMP ]
   Defined as 'positive' if no additional hemostatic intervention is required and hemoglobin levels decrease by <30% (after accounting for red cell transfusions) from 60 minutes to 24 hours after initiation of the first dose of IMP.
2. Compare the amount of chest tube drainage between the Octaplex and FP groups. [ Time Frame: 12 and 24 hours after chest closure ]
3. Compare the incidence of severe to massive bleeding between the Octaplex and FP groups using a modification of the universal definition of perioperative bleeding (UDPB). [ Time Frame: 24 hours after surgery start, after the end of CPB and after IMP initiation ]
4. Compare efficacy in terms of the mean number of total allogeneic blood components (IMP and non-IMP) transfused between the Octaplex and FP groups. [ Time Frame: 24 hours after the end of CPB and after IMP initiation ]
5. Compare efficacy in terms of the mean number of total non-IMP allogeneic blood components transfused between the Octaplex and FP groups. [ Time Frame: 24 hours after the end of CPB and after IMP initiation ]
6. Compare efficacy in terms of the mean number of total non-IMP allogeneic blood components transfused between the Octaplex and FP groups. [ Time Frame: 24 hours and 7 days after the end of CPB and after IMP initiation ]
7. Compare mean number of individual allogeneic blood components transfused between the Octaplex and FP groups. [ Time Frame: 24 hours and 7 days after start of surgery, and after the end of CPB and after IMP initiation ]
8. Compare efficacy in terms of the incidence of transfusion of individual allogeneic blood components transfused between the Octaplex and FP groups. [ Time Frame: 24 hours and 7 days after start of surgery and after the end of CPB and after IMP initiation ]
9. Compare incidence of administration of non-IMP coagulation factor products between Octaplex and FP groups [ Time Frame: 24 hours and 7 days after the start of surgery, after the end of CPB and after IMP initiation ]
10. Compare incidence of intracerebral hemorrhage between the Octaplex and FP groups [ Time Frame: 24 hours after start of surgery, after the end of CPB and after IMP initiation ]
11. Compare incidence of gastrointestinal hemorrhage between Octaplex and FP groups [ Time Frame: 24 hours after start of surgery, after the end of CPB and after IMP initiation ]
12. Compare incidence of surgical re-exploration between Octaplex and FP groups [ Time Frame: 24 hours after start of surgery, after the end of CPB and after IMP initiation ]
13. Compare the effect of Octaplex versus FP administration on the change in international normalised ratio (INR) before and after therapy administration. [ Time Frame: Within 30 minutes before to within 60 minutes after the initiation of IMP administration. ]
    INR reduction will be considered successful if the magnitude of the reduction is >1.0 or the post-treatment level drops below 1.5
14. Compare the effect of Octaplex versus FP administration on Prothrombin Time (PT) [ Time Frame: Within 75 minutes before to within 75 minutes after the initiation of IMP administration ]
15. Compare the effect of Octaplex versus FP administration on aPTT [ Time Frame: Within 75 minutes before to within 75 minutes after the initiation of IMP administration ]
16. Compare the effect of Octaplex versus FP administration on fibrinogen activity [ Time Frame: Within 75 minutes before to within 75 minutes after the initiation of IMP administration ]
17. Compare the effect of Octaplex versus FP administration on ROTEM EXTEM CT [ Time Frame: Within 75 minutes before to within 75 minutes after the initiation of IMP administration ]
18. Compare the effect of Octaplex versus FP administration on ROTEM EXTEM MCT [ Time Frame: Within 75 minutes before to within 75 minutes after the initiation of IMP administration ]
19. Compare the effect of Octaplex versus FP administration on ROTEM FIBTEM MCF [ Time Frame: Within 75 minutes before to within 75 minutes after the initiation of IMP administration ]
20. Compare the effect of Octaplex versus FP administration on platelets [ Time Frame: Within 75 minutes before to within 75 minutes after the initiation of IMP administration ]
21. Compare total time elapsed from initiation of the first dose of IMP to arrival at the ICU room between the Octaplex and FP groups. [ Time Frame: From initiation of IMP to arrival at ICU room (within 24 hours) ]
22. Comparison of incidence of serious treatment-emergent adverse events between Octaplex and FP groups [ Time Frame: From start of IMP administration up to 30 days post-operatively ]
23. Comparison of the duration of mechanical ventilation between Octaplex and FP groups [ Time Frame: From start of IMP administration up to 30 days post-operatively ]
24. Comparison of the duration of ICU stay between Octaplex and FP groups [ Time Frame: From start of IMP administration up to 30 days post-operatively ]
25. Comparison of the duration of hospitalization between Octaplex and FP groups [ Time Frame: From start of IMP administration up to 30 days post-operatively ]
26. Comparison of the incidence of death between Octaplex and FP groups [ Time Frame: From start of IMP administration up to 30 days post-operatively ]
27. Comparison of the number of days alive and out of hospital between Octaplex and FP groups [ Time Frame: From start of IMP administration up to 30 days post-operatively ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Adult (≥18 years old) patients undergoing any index cardiac surgery employing CPB

2. Coagulation factor replacement with PCC or FP ordered in the operating room for:

   1. Management of bleeding, or
   2. Anticipated bleeding in a patient who has been on-pump for >2 hours or has undergone a complex procedure (e.g., aortocoronary bypass [ACB] plus aortic valve replacement)
3. Coagulation factor deficiency, either known to exist (e.g., as indicated by elevated EXTEM clotting time [CT] or INR) or suspected based on the clinical situation
4. Patients who have given written informed consent. In United States patients will provide informed consent prior to surgery. In Canada, informed consent will be obtained after surgery, in accordance with Article 3.7A of the 2018 Tri- Council Policy Statement on the Ethical Conduct for Research Involving Humans.

Exclusion Criteria:

1. Undergoing heart transplantation, insertion or removal of ventricular assist devices (not including intra-aortic balloon pump [IABP]) or repair of thoracoabdominal aneurysm
2. Critical state immediately before surgery with high probability of death within 24 hours of surgery (e.g., acute aortic dissection, cardiac arrest within 24 hours before surgery)
3. Severe right heart failure (clinical diagnosis ± echocardiography)
4. Known contraindications to heparin
5. PCC required for reversal of warfarin or direct oral anticoagulant (DOAC; dabigatran, rivaroxaban, apixaban or edoxaban) within 3 days prior to or during surgery
6. Known thromboembolic event (TEE) within 3 months prior to surgery
7. History of severe allergic reactions to PCC or FP
8. Individuals who have immunoglobulin A (IgA) deficiency with known antibodies against IgA
9. Refusal of allogeneic blood products
10. Known pregnancy
11. Currently enrolled in other interventional clinical trials

Contacts and Locations

Contacts

Contact: Sigurd Knaub; +41795330529; Sigurd.Knaub@Octapharma.com

Locations

United States, North Carolina

Duke University Health System; Recruiting

Durham, North Carolina, United States, 27710

United States, Oklahoma

University of Oklahoma Health Sciences Center; Recruiting

Oklahoma City, Oklahoma, United States, 73104

Canada, British Columbia

Royal Columbian Hospital; Recruiting

New Westminster, British Columbia, Canada, V3L 3W7

University of British Columbia and Vancouver Coastal Health Authority; Not yet recruiting

Vancouver, British Columbia, Canada, V5Z 1M9

Canada, Ontario

Hamilton Health Sciences Corporation; Not yet recruiting

Hamilton, Ontario, Canada, L8L 8E7

Kingston General Hospital; Recruiting

Kingston, Ontario, Canada, K7L 2V7

London Health Sciences; Recruiting

London, Ontario, Canada, N6A 5A5

University of Ottawa Heart Institute; Not yet recruiting

Ottawa, Ontario, Canada, K1Y 4W7

Sunnybrook Hospital; Recruiting

Toronto, Ontario, Canada, M4N 3M5

St. Michael's Hospital; Not yet recruiting

Toronto, Ontario, Canada, M5B 1W8

Toronto General Hospital; Recruiting

Toronto, Ontario, Canada, M5G 2C4

Canada, Quebec

Montreal Heart Institute; Not yet recruiting

Montréal, Quebec, Canada, H1T 1C8

Quebec Laval; Recruiting

Québec, Quebec, Canada, G1V 4G5

Sponsors and Collaborators

Octapharma

More Information

• Responsible Party: Octapharma
• ClinicalTrials.gov Identifier: NCT05523297
• Other Study ID Numbers: LEX-211
• First Posted: August 31, 2022
• Last Update Posted: June 18, 2023
• Last Verified: June 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Hemorrhage; Pathologic Processes